Produktinformation
- Pirtobrutinib
LOXO-305 is a small molecule that inhibits the activity of venetoclax, an inhibitor of BCL2. LOXO-305 has shown efficacy in mouse models for chronic lymphocytic leukemia, which is a type of cancer that originates in white blood cells called lymphocytes. Venetoclax targets the BCL2 protein and inhibits its ability to keep lymphocytes from dying, and thus is used to treat chronic lymphocytic leukemia. Venetoclax also has minimal activity against other types of cancer cells, including those that are resistant to chemotherapy drugs such as doxorubicin or cisplatin. The safety profile for LOXO-305 is also very good with no observed toxicity in mice or monkeys up to doses of 500 mg/kg. This drug has been shown to be potently active in cellular models at concentrations below 10 μM, which may be due to inhibition of the venetoclax target or inhibition of other proteins involved in
Chemische Eigenschaften
Technische Anfrage zu: 3D-BL180882 LOXO-305
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.
